Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock. Chardan Capital’s price target suggests a potential upside of 208.37% from the company’s current price.

Several other analysts have also recently issued reports on TSHA. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday. Finally, Canaccord Genuity Group dropped their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $6.38.

Taysha Gene Therapies Price Performance

Shares of TSHA stock traded up $0.06 on Thursday, reaching $2.27. 10,301,981 shares of the company were exchanged, compared to its average volume of 2,596,387. The company has a market cap of $465.22 million, a price-to-earnings ratio of 3.60 and a beta of 0.44. The business has a 50-day moving average price of $1.98 and a 200 day moving average price of $2.39. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.22 and a current ratio of 5.22. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $3.62 million. During the same quarter in the prior year, the company earned ($0.38) EPS. Equities research analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in the stock. MetLife Investment Management LLC boosted its position in shares of Taysha Gene Therapies by 81.9% during the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after purchasing an additional 34,243 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Taysha Gene Therapies by 7.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after purchasing an additional 33,123 shares during the period. Intech Investment Management LLC purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $85,000. GSA Capital Partners LLP boosted its position in Taysha Gene Therapies by 64.7% in the 3rd quarter. GSA Capital Partners LLP now owns 233,560 shares of the company’s stock valued at $469,000 after buying an additional 91,755 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in Taysha Gene Therapies in the 3rd quarter valued at approximately $416,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.